Another example, combination therapy of pazopanib (VEGFR2 inhibitor) and abexinostat (HDAC inhibitor) showed that HDAC inhibition could improve response and holdback resistance to pazopanib in patients with solid tumour malignancies and renal cell carcinoma.11 This evidence concerns the gene HDAC9 and hereditary clear cell renal cell carcinoma.